Newsroom Archives - Page 17 of 23 - Spectral Medical Inc

Spectral to Present at the Benzinga Global Small Cap Conference on October 27, 2021

TORONTO, Canada – October 25, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that Chris Seto, Chief Executive Officer of Spectral, will present at the Benzinga...

Spectral and Dialco announce Dr. John Kellum to be featured as Keynote Lecturer AT the 39th Vicenza Course on AKI and CRRT

Dr. Kellum Invited to Participate on Additional Featured Panels TORONTO, Canada – October 20, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), are pleased to announce that Dr. John...

Spectral Medical’s CMO Recognized as a World Expert in Sepsis; Supports World Sepsis Day and Sepsis Awareness Month

Spectral Sponsors Live Webinar hosted by its CMO at the Sepsis Alliance Symposium September 13th is World Sepsis Day; September is designated as Sepsis Awareness Month TORONTO, CANADA — September 13, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:...

Spectral Medical Announces its Participation at Upcoming Investor Conferences

Toronto, Ontario | August 23, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing diagnostic and therapeutic options for septic shock as well as commercializing a new proprietary platform targeting the...

Spectral Medical Announces Internal Reorganization of its Wholly Owned Subsidiary. Dialco Medical to Enhance Operations and Accelerate Commercialization

Outlines anticipated milestones related to its DIMI and SAMI devices Toronto, Ontario | August 9, 2021 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) today announced an internal reorganization to strengthen the core competencies and management of its...

Spectral Medical Inc. Provides Tigris Clinical Trial Update

Recruitment activity returning to normalized levels with 12 trial sites actively screening patients 15 sites on track to open for enrollment by the end of Q3 2021 TORONTO, July 28, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.